# CSF2RB

Source: https://onco.cc/targets/csf2rb/  
OnCo record `csf2rb` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CSF2RB (Cytokine receptor common subunit beta) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Sarcomas, Leukaemia, Myeloproliferative neoplasms and 1 more.

## Summary

Cell surface receptor that plays a role in immune response and controls the production and differentiation of haematopoietic progenitor cells into lineage-restricted cells. Acts by forming an heterodimeric receptor through interaction with different partners such as IL3RA, IL5RA or CSF2RA. In turn, participates in various signalling pathways including interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor/CSF2 pathways.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Doxorubicin. Open Targets scores its association with cancer at 0.55 (direct and indirect evidence; datatypes literature 0.67, animal model 0.45, genetic association 0.00, clinical 0.86).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: colony stimulating factor 2 receptor subunit beta; Cytokine receptor common subunit beta; IL5RB; CD131; betaGMR; IL3RB
- Tags: cancer-genes-wave
- Symbol: CSF2RB
- Class: other
- Biology: Cell surface receptor that plays a role in immune response and controls the production and differentiation of haematopoietic progenitor cells into lineage-restricted cells. Acts by forming an heterodimeric receptor through interaction with different partners such as IL3RA, IL5RA or CSF2RA. In turn, participates in various signalling pathways including interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor/CSF2 pathways. In unstimulated conditions, interacts constitutively with JAK1 and ligand binding leads to JAK1 stimulation and subsequent activation of the JAK-STAT pathway. Location: Membrane (UniProt). Locus 22q12.3 (HGNC).
- Where found: Sarcomas: CIViC evidence names this disease; Leukaemia: Open Targets association 0.54 with leukaemia (MONDO_0005059); Myeloproliferative neoplasms: Open Targets association 0.53 with myeloproliferative neoplasm (MONDO_0020076); Acute myeloid leukaemia: Open Targets association 0.52 with acute myeloid leukaemia (MONDO_0018874)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.86; CIViC holds 1 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:2436: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2436
- UniProt P32927: https://www.uniprot.org/uniprotkb/P32927/entry
- NCBI Gene 1439: https://www.ncbi.nlm.nih.gov/gene/1439
- Ensembl ENSG00000100368: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100368

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)

---
JSON: https://onco.cc/api/v1/entities/csf2rb.json